PRO Consulting Expands Services to Meet Growing Client Needs
PRO Consulting® announced that it has expanded its line of Patient Reported Outcomes (PRO) services to support new biopharmaceutical and medical device developers as they implement PROs throughout all stages of their clinical development programs.
While many of the services offered by PRO Consulting are customized to meet individual client needs, developers of biopharmaceutical and medical device products are already benefiting from the expanded portfolio of strategic and tactical services offered by PRO Consulting. Services now being offered include:
- PRO Concept Evaluation & Conceptual Model Development Services
- PRO Instrument Evaluation, Selection, Modification, & Development Services
- PRO Data Management & Statistical Services
- PRO Regulatory Meeting Support Services
- PRO Translation & Linguistic Validation Services
- PRO Scientific Communications Services
- PRO Paper to Electronic Migration Services: Cognitive Interviews and Equivalence Studies
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
